



2Q23 Earnings Presentation

July 28, 2023

Disclaimer


Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its continued access to capital to fund its business plan. These forward-looking statements substantially depend on the market conditions, government regulations, competitive pressures, the performance of the Brazilian economy and the industry, among other factors, as well as the risks shown in our filed disclosure documents, and are therefore subject to change without prior notice.

In addition, unaudited information herein reflects management's interpretation of information taken from its financial statements and their respective adjustments, which were prepared in accordance with market practices and for the sole purpose of a more detailed and specific analysis of our results. Therefore, these additional considerations and data must also be analyzed and interpreted independently by shareholders and market agents, who should carry out their own analysis and draw their own conclusions from the information reported herein. No data or interpretative analysis provided by our management should be treated as a guarantee of future performance or results and are merely illustrative of our directors' vision of our results.

The management is not responsible for compliance or accuracy of the data from this report, which must be considered as for informational purposes only, and should not override the analysis of our audited consolidated financial statements for purposes of a decision to invest in our stock, or for any other purpose.

8.6%¹ of sell-out growth in 2Q23


> **SELL-OUT COMPOUNDED ANNUAL GROWTH 2Q21 vs. 2Q23**
+17.0% (0.4 percentage point above the market²)



2Q23 Highlights



2Q23 main launches



Non-Retail Market growth of 54.9%¹



Interest on Equity of R\$194.8 million (R\$0.31/share) in 2Q23

Note: ¹Does not consider the non-recurring sale of immunoglobulin

New composition of the Board of Directors

Álvaro Stainfeld (*Chairman*)

Accountant and MBA from Stanford University's Graduate School of Business, worked in Investment Banking at Goldman Sachs and is currently Portfolio Manager at MC Capital Group

Bernardo Malpica

Administrator and MBA from Kellogg Graduate School of Management, worked in important banks and brokerage houses in Mexico in several financial areas and is a partner of the investment bank Praemia

Esteban Malpica

Accountant and MBA from Notre Dame University, is the managing partner of the investment bank Praemia and former vice-president of the Mexican Stock Exchange

Hugo Leal

Lawyer and partner at Cescon, Barrieu, Flesch & Barreto Sociedade de Advogados, holds a master's degree in Tax Law from PUC/SP and in International Tax Law from NYU School of Law

Luciana de Queiroz

Engineer, worked in areas such as finance, planning, product marketing, mergers and acquisitions at Goldman Sachs, Arisco, Best Foods and Unilever

Dr. Flair Carrilho

Physician, head of Gastroenterology at Universidade de São Paulo (USP), head of the Division of Gastroenterology and Clinical Hepatology at USP's Hospital das Clínicas and full professor at USP

Maria Carolina Lacerda

Economist and MBA from Columbia University, has over 25 years of experience acting in important financial institutions and Boards of Directors in Brazil

Eliana Helena Chimenti

Lawyer and partner at Machado, Meyer, Sendacz e Opice Advogados and member of the Market Arbitration Chamber, has experience in corporate governance and mergers and acquisitions

Mauro Cunha

Economist, MBA from the University of Chicago and CFA from the CFA Institute, was president of IBGC and Amec and has acted as board member in several Boards of Directors in Brazil

2Q23 Highlights



2022 Integrated Annual Report



GPTW New Certification



6 brands in IstoÉ Dinheiro's most valuable brands ranking

2Q23 Results (R\$ million)

- **NET REVENUE**
R\$2,231.1 +17.7%¹
- **GROSS MARGIN**
63.2%² -50bps¹
- **MARKETING EXPENSES**
15.9%² -60bps¹
- **SELLING EXPENSES**
11.0%² +100bps¹
- **GENERAL AND ADMINISTRATIVE EXPENSES**
4.0%² +30bps¹
- **EBITDA MARGIN FROM CONTINUING OP. (excl. OTHERS)**
34.6%² -100bps¹
- **NET INCOME FROM CONTINUING OPERATIONS**
R\$504.4 +10.7%¹



2Q23 Cash Flow (R\$ million)

